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Cardiovascular disease is the leading cause of mortality in
chronic kidney disease (CKD). As matrix metalloproteinases
have a major role in atherosclerosis, we hypothesized that
alterations in metalloproteinases-8, -10 and their tissue
inhibitor-1 can be associated with the severity of
atherosclerosis in patients with kidney disease. This was
evaluated in a cross-sectional, observational study of 111
patients with stages I–V kidney disease, 217 patients on
dialysis and 50 healthy controls. The severity of
atherosclerosis was estimated with the atherosclerosis score
(AS), combining the results of ankle–brachial index and
carotid ultrasound. Serum levels of the two
metalloproteinases and tissue inhibitor-1 were measured by
enzyme-linked immunosorbent assay and were significantly
increased in patients with kidney disease compared with the
healthy controls, and higher in patients on dialysis than in
earlier stages of CKD. The severity of the AS was also more
prevalent in the dialysis group, in which serum levels of both
metalloproteinases and tissue inhibitor-1 were significantly
higher. After multivariate analysis, metalloproteinase-10,
dialysis, C-reactive protein, age, and male gender were
associated with increased risk of atherosclerosis. Thus,
patients with CKD exhibit elevated levels of circulating
metalloproteinase-10, and this was independently associated
with the severity of atherosclerosis and may represent a new
biomarker of atherosclerotic diseases.
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Cardiovascular diseases (CVD) are the leading cause of death
in patients with chronic kidney disease (CKD),1,2 and
cardiovascular risk is higher in such patients than in the
general population even at early stages of CKD.3–5 Several
factors have been involved in the high incidence of CVD in
CKD patients. The burden of traditional risk factors (high
blood pressure, diabetes mellitus) is higher in CKD than
in the general population6 and it is associated with non-
traditional variables such as anemia,7 oxidative stress,
endothelial dysfunction,8 and an increased prevalence of
inflammation as kidney function declines.9,10 Moreover, the
presence and severity of atherosclerosis is significantly higher
in CKD-affected patients at any group of age compared with
control subjects with normal kidney function.11
The balance between matrix metalloproteinases (MMPs)
and their specific tissue inhibitors (tissue inhibitor of
metalloproteinases, TIMPs) regulates the proteolysis of the
vascular extracellular matrix and is crucial for atherosclerosis
and plaque destabilization.12 The proteinase activities exerted
by MMPs have been implicated in some of the biological
processes associated with atherosclerosis and its ischemic
clinical manifestations, such as myocardial infarction and
stroke, and circulating MMP levels have been associated
with subclinical atherosclerosis and increased cardio-
vascular risk (reviewed by Ba¨ck et al.13). However, the roles
of MMPs and TIMP in the pathogenesis of atherosclerosis
in CKD are poorly understood. Among different MMPs,
we have paid special attention to MMP-8 and MMP-10.
Serum MMP-8 concentration is elevated in subclinical
atherosclerosis and is associated with worse cardiovascular
outcomes.14 Recent studies from our group have also shown
that different inflammatory/prothrombotic stimuli induce
a significant expression and secretion of MMP-10 by
human endothelial cells, and this is also found in human
atherosclerosis.15–17
We hypothesized that CKD is associated with alterations
of MMPs and TIMPs that may be related to the severity of
atherosclerosis in this clinical setting. Therefore, we measured
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the circulating concentrations of MMP-8, MMP-10, and
TIMP-1 in patients at different stages of CKD, and analyzed
the impact of MMPs in the atherosclerotic burden of these
patients.
RESULTS
General characteristics of the study population
We included 328 patients (61.2% females, 65 (13) years old)
and 50 age- and sex-matched controls (60% females, 64.9 (3)
years old). Demographic, laboratory, and atherosclerosis
assessment results are displayed in Table 1. We found
significant differences when laboratory values (not demo-
graphic and clinical data) were analyzed separately by sex, as
males presented with lower total, high-density lipoprotein,
low-density lipoprotein, and triglyceride concentration than
females, at every stage of CKD. This difference was not
observed in control subjects. Patients at stages IV–V of CKD
were significantly older than patients at earlier stages, patients
on dialysis, and controls. There were no significant
differences in gender distribution, although the prevalence
of diabetes mellitus, hypercholesterolemia, high blood
pressure, smoking status, and previous CVDs were signifi-
cantly higher in the group of CKD patients than in controls.
As previously described in the literature, patients on dialysis
had lower values of body mass index, diastolic blood
pressure, total cholesterol, high-density lipoprotein, and
low-density lipoprotein cholesterol (P-values overall o0.05,
Table 1) when compared with both groups of patients at
earlier stages of CKD and controls. Conversely, the
concentration of C-reactive protein was significantly higher
in the dialysis group than in the other groups.
CKD patients presented with significantly higher carotid
intima-media thickness (cIMT) values and higher prevalence
of carotid plaques than controls, although total and
low-density lipoprotein cholesterol concentrations were
significantly lower. Furthermore, the prevalence of carotid
atheromatous plaques was significantly higher in later stages
of CKD, reaching 79.1% of patients on dialysis (Po0.001,
Table 1). Similarly, more severe atherosclerosis score (AS) was
far more prevalent in stages IV–V and dialysis than in stages
I–III (73.5, 84.7, and 48.8%, respectively, Po0.001).
MMPs at different stages of CKD
The concentrations of MMP-8, -10, and TIMP-1 according to
the stage of CKD are displayed in Table 2. CKD patients exhi-
bited much higher (Po0.001) concentration of MMP-8, -10,
and TIMP-1 than controls. MMP-10 concentrations were
higher (P¼ 0.004) in those patients in the group of dialysis
Table 1 | Selected characteristics of the study population (N=378)
Controls, N=50 CKD stages I–III, N=43 CKD stages IV–V, N=68 Dialysis, N=217 P-value
Demographic data
Age, years (s.d.) 64.9 (3) 59.6 (11)w 69.2 (12)w 64.7 (12)w 0.001
Sex, female, N (%) 30 (60) 29 (67.4) 38 (55.9) 134 (61.6) 0.66
Diabetes mellitus, N (%) 8 (16) 34 (79.1) 43 (63.2) 146 (67.6) 0.02
High blood pressure, N (%) 32 (64) 37 (86) 63 (92) 130 (59) 0.001
Lipid-lowering treatment, N (%) 10 (20) 22 (51.2) 35 (51.5) 96 (44.2) 0.002
Smoking, N (%) 2 (4.2) 7 (16.7) 11 (18.3) 38 (17.6) o0.001
Previous CV disease, N (%) 3 (6) 5 (11.6) 17 (25) 87 (40.3) o0.001
Clinical and laboratory data
BMI, kg/m2 28.3 (4.3)* 29.4 (4.2) 28.6 (5.5) 25.6 (4.7)w o0.001
Systolic blood pressure, mm Hg 136 (22) 137 (16) 140 (24) 136 (24) 0.67
Diastolic blood pressure, mm Hg 82 (8)* 78 (10) 75 (10)w 71 (12)w o0.001
Glucose, mg/dl 108 (37) 112 (33) 108 (40) 116 (51) 0.54
Total cholesterol, mg/dl 221 (39)* 184 (27)w 171 (31)w 157 (35)w o0.001
HDL cholesterol, mg/dl 52 (12) 56 (17)w 52 (13) 47 (17)w 0.002
LDL cholesterol, mg/dl 147 (37)* 102 (25)w 91 (25)w 81 (30)w o0.001
Triglycerides, mg/dl 112 (53)* 138 (66) 142 (79) 148 (98)w 0.06
C-reactive protein, mg/l 0.45 (0.58)* 5.18 (7.6)w 6.07 (9.1)w 15.79 (28)w o0.001
Calcium, mg/dl NA 9.4 (0.3)w 9.1 (0.6)w 8.8 (0.6)w o0.001
Phosphorus, mg/dl NA 3.3 (0.5)w 3.9 (0.6)w 4.7 (1.4)w o0.001
Atherosclerosis burden
Carotid IMT, mm 0.74 (0.16)* 0.81 (0.14) 0.80 (0.16) 0.83 (0.16)w 0.008
Carotid plaque, N (%) 13 (28) 20 (46.6) 47 (69.1) 171 (79.1) o0.001
Ankle–brachial Index NA 0.95 (0.1) 0.90 (0.2) 1.01 (0.4) 0.06
Atherosclerosis score (AS) o0.001
AS 0/1, N (%) NA 22 (51.2) 18 (26.5) 33 (15.3)
AS 2/3, N (%) NA 21 (48.8) 50 (73.5) 183 (84.7)
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CV, cardiovascular; HDL, high-density lipoprotein; IMT, intima-media thickness; LDL, low-density
lipoprotein; NA, not assessed.
*Indicates Po0.005 in the post hoc analyses of Bonferroni when compared controls vs CKD stages I–III, IV–V, and dialysis.
wIndicates Po0.005 in the post hoc analyses of Bonferroni when compared dialysis vs CKD stages I–III and IV–V.
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than those on stages I–III (Bonferroni post hoc analyses).
Similarly, MMP-8 and TIMP-1 were significantly increased in
the group of dialysis when compared with the other groups
(Bonferroni post hoc analyses, Po0.005, Table 2).
MMPs and AS in CKD patients
We diagnosed 254 (77%) CKD patients with either mode-
rate or severe atherosclerosis (AS 2 or 3). CKD patients with AS
2/3 were significantly (Po0.001) older (67–11)) than those
with AS 0/1 (56 (15)). We did not find significant differences
between groups (AS 0/1 vs AS 2/3) pertaining to diabetes
mellitus, high blood pressure, treatment with lipid-lowering
agents, and smoking. Similarly, there were no differences in
body mass index and systolic blood pressure values. However,
patients diagnosed of moderate or severe atherosclerosis
presented with higher concentration of C-reactive protein than
those patients with no or mild atherosclerosis (14.4 (26) vs 5.6
(6), mg/l, P¼ 0.006). Conversely, lipid values (total, high-
density lipoprotein, and low-density lipoprotein cholesterol)
were significantly lower in the group with moderate or severe
atherosclerosis (data not shown).
We then analyzed the concentration of MMPs according to
the AS, and we found a significant (Po0.05) increase in the
concentrations of MMP-8, -10, and TIMP-1 in CKD patients
with moderate or severe atherosclerosis when compared with
those with no or mild atherosclerosis. We then analyzed markers
of atherosclerosis burden (cIMT (Figure 1) and number of
carotid plaques (Figure 2)) and their relationship with MMPs/
TIMP-1 according to the different stages of CKD. We did not
find significant correlations between cIMT and MMPs/TIMP-1
at the different stages of CKD, with the exception displayed in
Figure 1. In the group of patients under dialysis, the concen-
tration of MMP-10 was positively (Pearson coefficient 0.16) and
significantly (P¼ 0.01) associated with cIMT. Similarly, in
patients at CKD stages I–III, the concentration of TIMP-1 was
positively (Pearson coefficient 0.32) and significantly (P¼ 0.03)
related to cIMT. As displayed in the Figure 2, the severity of
carotid atherosclerosis (defined by the number of carotid
plaques) was related to significantly higher concentrations of
MMP-10 and -8. Those patients under dialysis with either 1–2
or multiple carotid plaques presented with significantly higher
concentrations of MMP-10 and -8, than patients without
plaques. These results were not reproduced in patients at
different stages of CKD and controls.
We also analyzed the impact of MMPs on the severity of
atherosclerosis in the multivariate analyses. Independent
variables were selected from the univariate analyses (Po0.10)
Table 2 | Serum MMPs concentration according to stages of CKD
Controls, N=50 CKD stages I–III, N=43 CKD stages IV–V, N=68 Dialysis, N=217 P-value
MMP-8, ng/mlw 11.21 (12) 30.75 (26)* 26.70 (21)* 43.03 (41)* o0.001
MMP-10, pg/ml 555 (173) 1513 (1096)* 1814 (853)* 2099 (1138)* o0.001
TIMP-1, ng/mlw 245.25 (90) 193.38 (75) 243.59 (62) 305.22 (120)* o0.001
Abbreviations: CKD, chronic kidney disease; MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor of metalloproteinases type-1.
*Indicates Po0.005 in the post hoc analyses of Bonferroni.
wMMP-8 was measured in 29 and TIMP-1 in 44 out of 50 controls.
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Figure 1 |Association between carotid intima-media thickness
(cIMT) and proteolytic markers in the study population.
Significant correlations between cIMT and concentration of matrix
metalloproteinase (MMP)-10 (a) and tissue inhibitor of
metalloproteinases type 1 (TIMP-1) (b) in patients under dialysis
and chronic kidney disease (CKD) I–III, respectively.
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Figure 2 |Distribution of matrix metalloproteinase (MMP)-10
and MMP-8 in patients under dialysis according to the
number of carotid plaques. *Analysis of variance,
P-value¼ 0.003 for MMP-10 and 0.001 for MMP-8. **Post hoc
analyses of Bonferroni; Po0.05 between no plaque and the other
groups. wPost hoc analyses of Bonferroni; Po0.05 between more
than two plaques and the other groups.
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and included: age, sex, CKD stage, C-reactive protein,
cardiovascular risk measured by score, previous CVDs,
diagnoses of diabetes mellitus, lipid-lowering therapy, and
the concentration of MMPs and TIMP-1. As the dependent
variable we selected the AS, and the significant results are
listed in Table 3. Being on dialysis, older age, male, and the
higher concentration of MMP-10 significantly increased the
risk of moderate or severe atherosclerosis (Table 3). Inter-
estingly, we did not find significant associations with the
previous diagnoses of CVD or the concentration of MMP-8
and TIMP-1.
DISCUSSION
Turnover of extracellular matrix proteins, crucial for athero-
sclerotic plaque development and rupture, is largely achieved
through the action of MMPs, which represent a major class of
matrix-degrading proteinases. We report herein that serum
MMP-8, 10, and TIMP-1 are abnormally increased in CKD
patients, in particular in those in dialysis. In addition, we
found that MMP-10 is associated with the severity of
atherosclerosis in CKD patients, thus indicating that MMP-
10 may represent a new biomarker of atherosclerosis in this
clinical setting.
It is well accepted that MMPs are key factors in
atherosclerosis, being implicated in intimal thickening and
in the subsequent plaque rupture.12,13,18 However, serum
concentrations of MMP-8 and -10 have not been previously
determined in CKD patients. MMP-8 levels correlate with the
presence and severity of coronary artery disease,14 and are
associated with carotid plaque instability after stroke and
subclinical atherosclerosis.19 Recently, our group reported
that MMP-10 is expressed in atherosclerotic plaques, being
almost undetectable in healthy arteries, and that endothelial
MMP-10 expression can be induced by inflammatory
stimuli.15–17 Similarly, systemic levels of MMP-10 correlate
with inflammatory markers and are associated with athero-
sclerosis.16,17
In this study, we found that the concentrations of
MMP-8, -10, and TIMP-1 were significantly increased in
dialysis patients compared with those on stages I–III.
Interestingly, when analyzing the concentration of MMPs
according to the severity of atherosclerosis, as assessed by the
AS, cIMT, and number of carotid plaques, we found that
concentrations of MMP-8, -10, and TIMP-1 were signifi-
cantly higher in the group of patients with more severe
atherosclerosis when compared with those with no or mild
atherosclerosis. Furthermore, in those subjects on dialysis
a positive and significant correlation between cIMT and
MMP-10 was found. Similarly, the concentration of TIMP-1
was significantly correlated with cIMT in patients at stages of
CKD I–III. In the multivariate analysis, we found that being
on dialysis, age, C-reactive protein, and the concentration of
MMP-10 were significantly associated with the risk of severe
atherosclerosis. Taken together, our results suggest that
circulating MMP-10 concentration is an independent risk
factor for atherosclerosis in CKD patients.
Our study has several limitations. This is a cross-sectional,
observational study, and therefore we do not have data
pertaining to the prognostic value of MMPs on the incidence
of CVD. We have to keep in mind, however, that we used a
validated score for atherosclerosis assessment, which has been
previously tested as a prognostic tool to better predict
coronary heart disease.20 Controls (n¼ 50) have been
obtained from a previous study, including 400 apparently
healthy subjects, and are age and sex matched with patients
under study. Furthermore, our control subjects are repre-
sentative of the general healthy population in Spain, as
similar results, in terms of cardiovascular risk factors, have
been obtained from two population-based cross-sectional
surveys.21,22 Despite the intrinsic limitations of a case–control
study, we are confident that controls data are representative
of healthy Spanish population, and then the conclusions of
the study remained valid.
Another limitation is the heterogeneity of the population
under study, with a predominance of those patients on
dialysis. This might be the reason why the strongest
association between atherosclerosis burden and MMPs has
been found in the group under dialysis, with the exception of
TIMP-1 in CKD stages I–III. Whether MMP-10 concentration
is significantly influenced by dialysis and has nothing related
to atherosclerosis development remains unknown, and
further studies should be performed.
We do think, however, that these limitations do not affect
the conclusion of the study, as the results of the multivariate
analyses are very conclusive, regarding the association of
MMP-10 to the severity of atherosclerosis. This observational
study should guide future research in experimental models,
in order to elucidate involved mechanisms and therapeutic
targets.
We did not perform mechanistic studies to ascertain the
source of the excess of MMPs in our patients. In addition to
the inflammation caused by subclinical atherosclerosis and
renal failure, there are various potential causes of MMP
elevation as found in CKD patients. For example, the host
response to the insult of pathogens results in increased
Table 3 |Multivariate analysis of atherosclerosis score in
patients with CKD
Odds
ratio
Confidence
interval (95%) P-value
CKD stage, dialysis vs I–III 1.57 1.19–2.07 0.001
Age, years 1.06 1.04–1.09 o0.001
Sex, female vs male 0.42 0.22–0.79 0.008
Previous CV disease, yes vs no 1.25 0.53–2.95 0.60
Diabetes mellitus, yes vs no 1.32 0.63–2.75 0.46
Lipid-lowering treatment, yes vs no 1.41 0.75–2.67 0.28
Score risk 0.84 0.30–2.33 0.74
C-reactive protein, mg/l 1.03 0.99–1.08 0.05
MMP-10, upper tertile vs first tertile 1.57 1.06–2.32 0.02
MMP-8, upper tertile vs first tertile 1.15 0.77–1.73 0.47
TIMP-1, upper tertile vs first tertile 1.00 0.65–1.54 0.97
Abbreviations: CKD, chronic kidney disease; CV, cardiovascular; MMP, matrix
metalloproteinase; TIMP-1, tissue inhibitor of metalloproteinases type-1.
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MMPs.23–25 MMPs could also be involved in vascular calcifi-
cation, which occurs pathologically in diabetes and CKD, as
well as during the normal ageing process.26,27 Vascular
calcification in patients with advanced stages of CKD is
associated with significant shorter survival, and its relationship
with MMPs will be a focus of research in the future.
In conclusion, for the first time, we found that serum
MMP-8, -10, and TIMP-1 are abnormally increased in CKD
patients, especially in those on dialysis, and that MMP-10 is
associated with more severe atherosclerosis. Albeit prelimi-
nary, the reported findings set the stage for further studies
aimed at determining whether serum MMP-10 may be of
prognostic value in assessing the risk of atherosclerotic events
in CKD patients.
MATERIALS AND METHODS
Design
This is a cross-sectional, observational study, performed in
collaboration between the University-based Hospital Arnau de
Vilanova and the Center for Applied Medical Research of the
University of Navarra. The protocol has been reviewed and approved
by the Institutional Ethical Review Board of the Hospital, and each
participant has signed the informed consent. Inclusion period was
set at 6 months, during which we consecutively invited patients to
participate.
Study population
We included both modalities of dialysis (N¼ 217), hemodialysis
(N¼ 191), and peritoneal dialysis (N¼ 26). We did not exclude
participants according to age, previous CVDs, or concomitant
medical conditions, with the aim to have a representative population
on dialysis.
We similarly recruited patients at earlier stages of CKD, I–IV, and
V (No D), defined as recommended by current guidelines,28 from
the specialized nephrology outpatient clinic.
We also included healthy subjects as controls, as described in a
previously published article.29 Briefly, we identified 50 age- and sex-
matched subjects, with normal kidney function (according to
creatinine (mean (s.d.): 0.83 (0.18) mg/dl) and AC-MDRD-4
estimation), who attended the outpatient service of the Department
of Internal Medicine at the University Clinic of Navarra for a general
check-up. Carotid ultrasound was performed using the same
standard operational procedure as in patients (see below), and the
technician was blind to demographic and clinical characteristics of
participants. Ankle–brachial index (ABI) was not assessed in this
subset of participants.
Procedures and variables
Demographic, clinical, and laboratory variables were recorded in a
unitary database. Highly specialized personnel, blinded to partici-
pant-related information, performed the procedures, which con-
sisted in a standardized protocol for the non-invasive assessment of
atherosclerosis: carotid, abdominal ultrasound, and ABI, as recently
published.11
1. Carotid ultrasound: to measure cIMT and to identify carotid
plaques. We used a MicroMaxx, SonoSite (Bothell, WA, USA) with a
linear transducer HFL38/13-6 MHz. Briefly, the protocol consists in:
K Cross-sectional loop of the region of interest (common
carotid, bulb, and internal) to identify atheroma plaques.
K Longitudinal images: as it is defined in the consensus,30 we
analyzed the far wall of the common carotid artery in the last
centimeter, bulb section and finally internal carotid artery in the first
centimeter. The measurement of the cIMT is performed using the
semi-automated, Food and Drug Administration-approved software,
SonoCalc IMT (Bothell, WA, USA).
K Pulsed-Doppler: we use the color and pulsed-Doppler once an
atheromatous plaque is identified (significant stenosis considered
when systolic velocity peak 4125 cm/s is reached).
2. Abdominal ultrasound: to measure the presence of aortic
aneurysm, using a convex transducer C60 (Bothell, WA, USA).
3. Measurement of ABI: we used a vascular Doppler MD2
Hungleight (Bothell, WA, USA) with an 8 MHz transducer.
We used maximum brachial systolic pressures and recorded ABI
as the lowest value obtained at each territory.
We set an AS, according to previous literature,11,20 as follows:
1. No atherosclerosis (AS 0): ABI40.9 and cIMT inferior to the cut-
off value representing the 80% reference interval adjusted by age
and sex. Reference interval values have been obtained from
previously published observational studies using the same
ultrasound procedures.31,32
2. Mild atherosclerosis (AS 1): an ABI 0.7–0.9 and/or cIMT superior
to the cut-off value of the 80% reference interval.
3. Moderate atherosclerosis (AS 2): the presence of a carotid plaque
without significant stenosis (o125 cm/s) and ABI X0.7.
4. Severe atherosclerosis (AS 3): an ABIo0.7 and/or the presence of
a carotid plaque with significant stenosis (4125 cm/s).
We did not include the results of abdominal scan in the AS, as we
did not find any patient with abdominal aortic aneurysms.
For statistical purposes and clear display results, we have grouped
patients with AS 0 and AS 1 in one group (no and mild
atherosclerosis) and patients with AS 2 and AS 3 in another group
(moderate and severe atherosclerosis).
Laboratory analyses
MMP-8, 10, and TIMP-1 were assayed by specific enzyme-linked
immunosorbent assay (Quantikine, R&D Systems, Abingdon, UK)
according to the manufacturer’s instructions with a serum dilution
of 1:50, 1:1, and 1:100, respectively. The interassay coefficients
of variation were o8% and detection limit for the assays were
0.31 ng/ml, 78.1 pg/ml, and 0.15 ng/ml.
Statistical analyses
Results are expressed as mean (s.d.). Univariate descriptive statistics
were performed and differences among CKD types (I–III, IV–V
without and with dialysis) and controls were tested using the
analysis of variance test for comparisons between means of
numerical variables, the Kruskal–Wallis test to compare the medians
of numerical skewed variables, and the Pearson w2-test to compare
frequency distributions of categorical variables (substituted by
Fisher exact test when needed). We applied post hoc analyses
(Bonferroni tests) for multiple paired comparisons among CKD
types and controls. The AS classification (from AS 0 to AS 3) was
used to study atherosclerosis burden and its related variables, once
recoded into two groups to extract those with moderate or severe
atherosclerosis (AS 2 and 3). In order to identify the impact of
MMPs on the prediction of moderate or severe atherosclerosis, a
multivariate logistic regression model was estimated. Dependent
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variables were identified in the univariate analyses as those related to
the presence of atherosclerosis (AS 2 or 3, Po0.10 in the univariate
analyses) or those variables that might have a confounding effect.
We included in the analyses: sex, age, stage of CKD (dialysis vs CKD
stages I–III), previous CVD, type 2 diabetes mellitus, treatment with
statins, cardiovascular risk score, C-reactive protein concentration,
and MMP-8, 10, and TIMP-1, expressed as tertiles. We keep in the
model only those characteristics with a statistically significant
relationship (P-valueo0.05) or a confounding effect over any of the
coefficients of the rest of the variables.
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